The QT interval and the atypical antipsychotic, sertindole

International Journal of Psychiatry in Clinical Practice

Volumn 2, Issue 4, 1998, Pages 265-273

  Fritze, Jürgen ^a,b   Bandelow, Borwin ^c  

^a Assoc of Private Health Insurances   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antipsychotics; QT interval; Safety; Schizophrenia; Sertindole

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; POTASSIUM; POTASSIUM CHANNEL; RISPERIDONE; SEROTONIN 2 RECEPTOR; SERTINDOLE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG QT SYNDROME; MORTALITY; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES;

EID: 0032411856     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.3109/13651509809115372     Document Type: Article

References (42)

1. Wagstaff AJ, Bryson HM (1995) Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 4: 370-400.
2. Lamarque V (1996) Clozapine associated-agranulocytosis: A review of the international experience. Encephale 22: 35-6.
3. Möller HJ, Muller H, Borison RL et al (1995) A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a reevaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45-9.
4. Tollefson GD, Sanger TM (1997) Negative symptoms: a path-analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466-74.
5. Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a metaanalysis. Int Clin Psychopharmacol 10: 207-13.
6. Committee for Proprietary Medicinal Products: Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia. CPMP/EWP/559/95, London. 26 February 1998.
7. Daniel DG, Wozniak P, Mack RJ et al (1998) Long-term efficacy and safety comprison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 34: 61-9.
8. Tran PV, Hamilton SH, Kuntz AJ et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407-18.
9. Song F (1997) Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 11: 65-71.
10. Weaver MG (1997) Olanzapine-pharmacology and clinical evaluation of a new atypical antipsychotic. J Serotonin Res 4: 145-57.
11. Tamminga CA, Mack RJ, Granneman GR et al (1997) Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. Int Clin Psychopharmacol 12: S29-S35.
12. van Kammen DP, McEvoy JP, Targum SD (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168-75.
13. Zimbroff DL, Kane JM, Tamminga CA et al (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782-91.
14. Anon (1997) Zum Risikoprofil von Sertindol (Serdolect). Arznei-Telegramm 10: 128
15. Anon (1997) Neue "atypische" Neuroleptika: Olanzapin (Zyprexa)/Sertindol (Serdolect). Arznei-Telegramm 10: 103-5.
16. Beasley CM, Tollefson GD, Tran PV et al (1997) Safety of olanzapine. J Clin Psychiatry 58: 13-17.
17. Flugelman MY, Tal A, Pollack S et al (1985) Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 46: 290-1.
18. Parsons M, Buckley NA (1997) Overdose of antipsychotic drugs: practical management guidelines. CNS drugs 7: 427-41.
19. Buckley NA, Whyte IM, Dawson AH et al (1995) Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 33: 199-204.
20. Kiriike N, Maeda Y, Nishiwaki S et al (1987) latrogenic torsade de pointes induced by thirodazine. Biol Psychiatry 22: 99-103.
21. Baker B, Dorian P, Sandor P et al (1997) Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 17: 15-21.
22. Guy S, Silke B (1990) The electrocardiogram as a tool for therapeutic monitoring: A critical analysis. J Clin Psychiatry 51: 37-9.
23. Hewer W, Rost W, Gattaz F (1995) Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 246: 1-6.
24. Kresse Hermsdorf M, Muller Oerlinghausen B (1990) Tricyclic neuroleptic and antidepressant overdose: epidemiological, electrocardiographic, and clinical features-a survey of 92 cases. Pharmacopsychiatry (Suppl) 23: 17-22.
25. Van de Merwe TJ, Silverstone T, Ankier SI (1984) Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients. Curr Med Res Opin 9: 339-52.
26. Di Salvo TG, O'Gara PT (1995) Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 18: 285-90.
27. Henderson RA, Lane S, Henry JA (1991) Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose. Hum Exp Toxicol 10: 59-62.
28. Jackson T, Ditmanson L, Phibbs B (1997) Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 157: 2013-5.
29. Kriwisky M, Perry GY, Tarchitsky D et al (1990) Haloperidol-induced torsade de pointes. Chest 98: 482-4.
30. Lawrence KR, Nasraway SA (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17: 531-7.
31. Metzger E, Friedman R (1993) Prolongation of the corrected QT and torsade de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psycho-pharmacol 13: 128-32.
32. Fulop G, Phillips RA, Shapiro AK (1987) ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 144: 673-5.
33. Ravin DS, Levenson JW (1997) Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 31: 867-70.
34. Suessbrich H, Schonherr R, Heinemann SH et al (1997) The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120: 968-74.
35. Franz MR (1994) Time for yet another QT correction algorithm? Bazett and beyond. J Am Coll Cardiol 23: 1554-6.
36. Garson AJ (1993) How to measure the QT internal - what is normal? Am J Cardiol 72: 14B-16B.
37. Karjalainen J, Viitasalo M, Manttari M et al (1994) Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 23: 1547-53.
38. Higham PD, Campbell RWF (1994) QT dispersion. Br Heart J 71: 508-10.
39. Doig J (1995) Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Safety 17: 265-75.
40. Drici MD, Wang WX, Woosley RL (1996) Comparison of risperidone, olanzapine and sertindole on QT interval in isolated feline hearts. Presented at 35th Annual American College of Neuropsychopharmacology Meeting, Puerto Rico, 7-13 December 1996, Abstract book p. 265.
41. Barnett AA (1997) Safety concerns over antipsychotic drug, sertindole. Lancet 348: 256.
42. Ereshefsky L (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57: 12-25.